| 26.20 Data as of May 24 |  -0.27 / -1.02%Today’s Change | 20.67 Today|||52-Week Range 26.51 | +21.80% Year-to-Date |
| Elan Rejects Royalty Offer Again - Analyst Blog May 24 / Zacks.com | Toll Reports Better-than-Expected Earnings: Ahead of the Ticker May 22 / TheStreet.com |
| Want to invest in Samsung? Good luck! May 24 / CNNMoney.com | XenoPort Candidate Disappoints - Analyst Blog May 21 / Zacks.com |
| Impax Launches Generic Zomig - Analyst Blog May 23 / Zacks.com | Elan Provides Strategic Update - Analyst Blog May 21 / Zacks.com |
| Data on UCB's Neupro - Analyst Blog May 22 / Zacks.com | GlaxoSmithKline Stock Hits New 52-Week High (GSK) May 21 / TheStreet.com |
| XenoPort Resumes Horizant Supply - Analyst Blog May 22 / Zacks.com | Dirty Medicine May 15 / Fortune |
| Previous close | 26.47 |
| Today’s open | 26.51 |
| Day’s range | 26.20 - 26.51 |
| Volume | 3,600 |
| Average volume (3 months) | 5,316 |
| Market cap | $130.4B |
| Dividend yield | 4.89% |
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -- |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | -- |
| Price/Sales | -- |
| Price/Book | -- |
| No competitors data available. |
| Next reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | -- |
| Annual profit (last year) | -- |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters --, -- |
.
